SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Inclusion Criteria

• •Age \>=18 years, either sex, any race.
• •Histologically or cytologically confirmed breast cancer or NSCLC; and radiographic or clinically advanced disease.
• •BREAST CANCER:
• •* participant must have previously received both a taxane and an anthracycline (unless anthracycline therapy is contraindicated) in the adjuvant and/or metastatic setting,
• •* participant with HER2-positive disease must have progressed after trastuzumab and concomitant or subsequent lapatinib,
• •* participant must have received at least one, but no more than two prior regimens for recurrent or metastatic disease (endocrine and biologic therapies do not count as chemotherapeutic regimens).
• •NSCLC: at least one, but no more than two prior chemotherapeutic regimens for advanced disease.
• •Measurable disease by the RECIST.
• •Eastern Cooperative Oncology Group performance status of 0, 1, or 2.
• •Adequate hematologic, renal, and hepatic organ function and laboratory parameters.
• •Ability to swallow tablets.